SinoMab Bioscience Ltd.
SinoMab Bioscience Ltd. (3681) is a biopharmaceutical company based in Hong Kong, focused on the research, development, and commercialization of innovative monoclonal antibody therapies for the treatment of autoimmune diseases and cancers. The company operates primarily in the biotechnology sector, leveraging its proprietary technologies to develop a pipeline of therapeutics aimed at addressing unmet medical needs. SinoMab's core products include monoclonal antibodies that are currently in various stages of clinical development, targeting conditions such as rheumatoid arthritis and other immune-mediated disorders.